Dear Colleagues

Following our quite successful 2011 Munich conference on “Radiation Oncology in Prostate Cancer”, we are proud once again to host a radiation oncology meeting distinguished by renowned speakers and chairs. The scientific program has been organized in close cooperation with the radiation oncology departments of the “Technische Universität München” and the “Krankenhaus Barmherzige Schwestern Linz”. This year, we have included bladder cancer as a second disease entity, which similar to prostate cancer, is a urologic tumor that can be cured by radio(chemo)therapy. In addition, new topics such as stereotactic prostate radiation therapy, focal treatment and laser based protons are integral parts of this conference. New developments with regard to imaging, hypofractionation, brachytherapy and treatment of recurrence are being eagerly awaited and will be discussed. The meeting will be concluded with our ritual “battle” between dedicated followers of proton versus photon treatment.

2013 is a special year for the Department of Radiation Oncology of the TU München as both Prof. Molls and Prof. Geinitz are leaving the clinic. Thus, the pre-conference on March 7th entitled “37 years of radiation research – a Darwinian evolution?” is dedicated to highlighting the development of radiobiology, medical physics and radiooncology during the last three decades. Fellow research colleagues and clinical partners of Prof. Molls will be leading us through the program.

We are confident that the conference will again provoke vivid discussions and may even contribute to the further evolution of radio-uro-oncology. We look forward to seeing you in pre-spring in the Bavarian capital where the “Biergarten” and palace parks will be beginning to flourish.

Congress Venue:
Klinikum rechts der Isar, Technische Universität München
Hörsäle (Lecture halls)
Ismaninger Straße 22, 81675 Munich, Germany

Organization:
Department of Radiation Oncology
Technische Universität München
Barbara Hofbauer, Dipl.-BW
For registration and further information please visit: www.prostate-radiation-oncology.de

Contact:
vokativ GmbH, roc@vokativ.de
T: 0049-551-48857-409

Early bird registration (until January 18th, 2013):
170 Euros
Late and onsite registration:
230 Euros

Students:
Early bird registration (until January 18th, 2013):
50 Euros
Late and onsite registration:
70 Euros

The conference fee includes participation in the pre-conference on Thursday (March 7th, 2013). The Social Dinner on March 8th will be charged with 30 Euros.

CME points:
Pre-conference: 7 points
Main conference: 13 points
(Bayerische Landesärztekammer)

Radiation Oncology in Prostate and Bladder Cancer – Current and Future Concepts
Prof. Michael Molls:
37 Years of Radiation Research and 21 Years at the TU München

Pre-Conference: March 7, 2013
Conference: March 8 - 9, 2013

Klinikum rechts der Isar
Technische Universität München (TU Munich)
Radiation Oncology in Prostate and Bladder Cancer – Current and Future Concepts

Pre-Conference - 37 Years of Radiation Research
A Darwinian Evolution?

Thursday, March 7, 2013
Hörsaal (Lecture hall): Pavilion

12:00 – 12:15 Welcome address
Hans Geinitz, Chair Department of Radiation Oncology LInz
Peter Henningsen, Dean Medical Faculty, TUM

12:15 - 12:40 Keynote lecture
Chair: J. Wilkens
Interdisciplinary research at the interface of physics and biomedicine: the benefit for modern societies and the MAP Cluster of Excellence.
F. Kratz, Munich

12:40 - 13:00 From pre-implantation mouse embryos to cancer stem cells to combined radiation- and heavy ions.
F. Pfeiffer, Munich

13:00 - 13:20 Hypoxia – still a threat for radiation oncology and radiation oncologists?
V. Paupert, Munich

T. Schmidt, Munich

13:35 - 13:55 Normal tissue radiation injury: how will radiobiology help to save organs at risk?
M. Atkinson, Munich

13:55 - 14:15 Discussion

14:15 - 14:35 Coffee break

Medical physics evolution
Chairs: P. Kernschaar, N. Zamboglou

14:35 - 14:55 Radiotherapy facilities – do we need all the fancy novelties?
F. Nüsslin, Munich

14:55 - 15:15 Stereotactic body radiotherapy – successful implementation as a consequence of close cooperation of radiation oncology and medical physics.
F. Zimmermann, Basel

15:15 - 15:35 IMRT and protons: is the driver for the disease for a better treatment?
T. Bortfeld, Boston

15:35 - 15:55 Discussion

15:55 - 16:15 Coffee break

K. R. Trott, Munich

16:35 - 16:55 Where are the innovations in clinical and translational research in radiation oncology?
A. Grosu, Freiburg

16:55 – 17:15 Treatment concepts – innovation triggered by patients?
C. Nieder, Bochum

17:15 – 17:35 Scientific ethics and clinical studies.
P. Lukas, Innsbruck

17:35 – 17:55 Discussion

17:55 – 18:15 Michael Molls: 37 years of radiation research.
T. Herrmann, Dresden

18:15 End of pre-conference

Conference - Radiation Oncology in Prostate and Bladder Cancer

Friday, March 8, 2013
Hörsaal (Lecture hall): A

08:30 - 08:40 Welcome address
Hans Geinitz, Chair Department of Radiation Oncology Linz
Reiner Gradinger - Medical Director TUM
Michael Molls, Chair Department of Radiation Oncology TUM

08:40 - 09:00 Imaging and delineation
Chairs: A. Grosu, E. Rummey

09:00 - 09:20 New X-ray imaging modalities: will brilliant CT come into the clinic in the upcoming years?
F. Pfeiffer, Munich

09:20 - 09:40 New PET tracers and biomarkers for the staging of prostate cancer.
W. Lileybo, Oslo

09:40 - 09:40 MRI imaging: sensitivity and specificity for intraprostatic lesion boost.
M. Reiser, Munich

09:40 - 10:00 Safety margins with IMRT and IGRT: how much is large enough?
F. Wenz, Mannheim

10:00 - 10:20 Discussion

10:20 - 10:40 Coffee Break

10:40 - 11:00 Radiation therapy techniques
Chairs: S. Fossa, D. Vordermark

11:00 - 11:20 IMRT for prostate cancer – total doses and dose constraints.
S. Fossa, Oslo

J. Dunst, Lübeck

11:40 - 12:00 Discussion

12:00 - 12:20 Coffee Break

12:20 – 12:40 ... with regard to overall survival
Chairs: P. Warde, JH Kaanders

12:40 – 13:00 Does surgery increase the survival in patients with prostate cancer?
J. Herrmann, Würzburg

13:00 – 13:20 More late toxicity and decreased quality of life – the trade-offs for a better survival?
R. Pötter, Wien

13:20 – 13:40 Discussion

13:40 – 15:10 Lunch and industrial exhibition

11:00 - 11:20 Systemic therapy for biochemical recurrence: how and when?
H. Kübler, Munich

11:20 - 11:40 Recurrence after radiation therapy: local therapy: how and when?
W. Loidl, Linz

11:40 - 12:00 Discussion

12:10 - 13:30 Lunch and industrial exhibition

12:40 – 13:00 Does surgery for bladder cancer come into the clinic in the upcoming years?
M. Flentje, Würzburg

13:20 – 13:40 Discussion

13:40 – 14:00 Hypofractionation or acceleration for prostate cancer.
D. Böhm, Berlin

14:00 - 14:20 Comparative trials on radiation therapy vs. surgery for prostate cancer.
A. Grosu, E. Rummey

14:20 – 14:40 Hypofractionation or acceleration for prostate cancer – total doses and dose constraints.
J. Durb, Heidelberg

14:40 – 15:00 Discussion

15:00 – 15:20 Hypofractionation and stereotactic treatment
Chairs: D. Deamens, N. Duma

15:20 – 15:40 Hypofractionation or acceleration for prostate cancer.
D. Deamens, London

15:40 - 16:00 Stereotactic treatment for prostate cancer: how and why?
M. Guckenberger, Würzburg

16:00 - 16:20 Hypofractionation or acceleration for bladder cancer?
S. Combs, Heidelberg

16:20 – 16:40 Discussion

17:10 – 17:30 Coffee Break

17:30 – 17:50 Hypofractionation and stereotactic treatment
Chairs: D. Deamens, N. Duma

17:50 – 18:10 Stereotactic treatment for prostate cancer: how and why?
M. Guckenberger, Würzburg

18:10 – 18:30 Hypofractionation or acceleration for bladder cancer?
S. Combs, Heidelberg

18:30 – 18:50 Discussion

19:00 Conference dinner

Saturday, March 9, 2013
Hörsaal (Lecture hall): A

9:00 - 9:20 Brachytherapy
Chairs: K. Kopp, O. Kühl

9:20 - 9:40 HDR brachytherapy: new techniques and recent trials.
N. Zamboglou, Offenbach

9:40 - 10:00 Discussion

10:00 - 10:20 Coffee Break

10:20 - 10:40 Treatment of recurrence
Chairs: H. Geinitz, F. Sedlmayer

10:40 - 11:00 Biochemical recurrence after definitive radiotherapy – how long can we watch and wait?
F. Lohr, Mannheim

11:00 - 11:20 Recurrence after radiation therapy: local therapy: how and when?
M. Loidl, Linz

G. Goldstein, Wien

11:40 - 12:00 Discussion

12:10 - 13:30 Lunch and industrial exhibition

12:40 – 13:00 Controversy: protons and heavy ions vs. photons.
S. Molls, V. Budach

13:00 – 13:50 Treating patients on trials in proton facilities: where do we stand?
R. Schnieder, Villigen

13:50 - 14:10 New evidence for the superiority of protons or heavy ions in prostate cancer treatment.
D. Deamens, Heidelberg

14:10 - 14:30 New evidence against the superiority of protons or heavy ions in prostate cancer treatment.
N. van As, Sutton

14:30 - 15:40 Discussion

15:40 Closing Remarks